HIV

Skye Opsteen is a first-generation MD/PhD trainee in the Medical Scientist Training Program at the University of Alabama at Birmingham, Birmingham, AL, USA. Under the mentorship of Dr Nathan Erdmann, her PhD research explores the impact of chronic HIV infection on the manifestations and pathogenesis of long COVID. With a long-term goal of investigating infectious […]

“An HIV vaccine wouldn’t just save lives; it would transform entire communities” Despite decades of research and advances in HIV treatment, an effective vaccine is still in development. The disease’s ability to mutate, evade the immune system and persist in the body presents unique scientific challenges. However, recent innovations in vaccine technology, including mRNA and […]

The Conference on Retroviruses and Opportunistic Infections (CROI) is the leading global meeting for HIV research, bringing together over 4,000 experts from around the world. It serves as a platform for researchers to translate laboratory and clinical discoveries into meaningful advancements in the fight against the HIV pandemic. CROI has played a pivotal role in […]

The world can eliminate AIDS by empowering communities and prioritizing human rights. We can end AIDS as a global health threat by 2030.   The World Health Organization (WHO) joined forces with partners and communities to commemorate World AIDS Day 2024 (1 December), themed “Take the rights path: My health, my right!”. This year’s campaign […]

As 2024 draws to a close, we’re celebrating a wonderful year of content. From insightful expert Q&As and peer-reviewed articles to conference highlights and a wealth of medical education, it’s been a year filled with content that we hope has been useful to our audience. We’ve had the privilege of connecting with leading experts and working alongside medical societies to support the infectious diseases community with high-quality, easily accessible content.

Topline results from phase III PURPOSE 1 trial (NCT04994509) demonstrate the twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, achieved 100% efficacy in preventing HIV infections in cisgender women.